The tumor microenvironment in non-small-cell lung cancer

Seminars in Radiation Oncology

Volumn 20, Issue 3, 2010, Pages 156-163

  Graves, Edward E ^a   Maity, Amit ^a   Le, Quynh Thu ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CISPLATIN; ERLOTINIB; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NELFINAVIR; NITROIMIDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TIRAPAZAMINE; TRACER; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; WORTMANNIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; HEAD AND NECK CARCINOMA; HUMAN; LUNG CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ACIDOSIS; ANOXIA; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954836067     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2010.01.003     Document Type: Review

References (95)

1. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252.
2. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408-1416.
3. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-549.
4. Graeber T.G., Peterson J.F., Tsai M., et al. Hypoxia induces the accumulation of p53 protein, but the activation of a G1-phase checkpoint by low oxygen conditions is independent of p53 status. Mol Cell Biol 1994, 14:6264-6277.
5. Le Q.T., Denko N.C., Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004, 23:293-310.
6. Papandreou I., Cairns R.A., Fontana L., et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006, 3:187-197.
7. Tatum J.L., Kelloff G.J., Gillies R.J., et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82:699-757.
8. Le Q.T., Chen E., Salim A., et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006, 12:1507-1514.
9. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003, 2:803-811.
10. Nakao M., Ishii G., Nagai K., et al. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 2009, 115:2732-2743.
11. Le Q.T., Shi G., Cao H., et al. Galectin-1: A link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005, 23:8932-8941.
12. Le Q.T., Kong C., Lavori P.W., et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007, 69:167-175.
13. Erler J.T., Bennewith K.L., Nicolau M., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
14. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway-A report of the Tumour Angiogenesis Research Group. J Clin Oncol 2006, 24:4301-4308.
15. Giatromanolaki A., Koukourakis M.I., Sowter H.M., et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res 2004, 10:5566-5571.
16. de Witte J.H., Sweep C.G., Klijn J.G., et al. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer 1999, 79:1190-1198.
17. Linderholm B.K., Lindh B., Beckman L., et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer 2003, 4:340-347.
18. Zhan P., Wang J., et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: A systematic review with meta-analysis. Lv. J Thorac Oncol 2009, 4:1094-1103. XJ.
19. Le Q.T., Sutphin P.D., Raychaudhuri S., et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003, 9:59-67.
20. Mack P.C., Redman M.W., Chansky K., et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. J Clin Oncol 2008, 26:4771-4776.
21. Overgaard J., Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996, 6:10-21.
22. Shaw E., Scott C., Suh J., et al. RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 2003, 21:2364-2371.
23. Kaanders J.H., Pop L.A., Marres H.A., et al. Arcon: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 52:769-778.
24. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCA) protocol 5-85. Radiother Oncol 1998, 46:135-146.
25. Britten R.A., Peters L.J., Murray D. Biological factors influencing the RBE of neutrons: Implications for their past, present and future use in radiotherapy. Radiat Res 2001, 156:125-135.
26. Treat J., Johnson E., Langer C., et al. Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer: A phase II study. J Clin Oncol 1998, 16:3524-3527.
27. von Pawel J., von Roemeling R., Gatzemeier U., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000, 18:1351-1359.
28. Shepherd F., Koschel G., von Pawel J., et al. Comparison of Tirazone (tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international phase III catapult II Trial. Lung Cancer 2000, 29:28.
29. Williamson S.K., Crowley J.J., Lara P.N., et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group trial S0003. J Clin Oncol 2005, 23:9097-9104.
30. Le Q.T., McCoy J., Williamson S., et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): A Southwest Oncology Group study. Clin Cancer Res 2004, 10:5418-5424.
31. Le Q.T., Moon J., Redman M., et al. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol 2009, 27:3014-3019.
32. Nehmeh S.A., Lee N.Y., Schroder H., et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008, 70:235-242.
33. Baumann P., Nyman J., Lax I., et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006, 45:787-795.
34. Koto M., Takai Y., Ogawa Y., et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007, 85:429-434.
35. Goodman K.A., Sneed P.K., McDermott M.W., et al. Relationship between pattern of enhancement and local control of brain metastases after radiosurgery. Int J Radiat Oncol Biol Phys 2001, 50:139-146.
36. Tofts P., Brix G., Buckley D., et al. Estimating kinetic parameters from dynamic contrast-enhanced t 1-weighted MRI of a diffusible tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232.
37. Naish J.H., Kershaw L.E., Buckley D.L., et al. Modeling of contrast agent kinetics in the lung using T1-weighted dynamic contrast-enhanced MRI. Magn Reson Med 2009, 61:1507-1514.
38. Schaefer J.F., Vollmar J., Schick F., et al. Solitary pulmonary nodules: Dynamic contrast-enhanced MR imaging-Perfusion differences in malignant and benign lesions. Radiology 2004, 232:544-553.
39. Lin W., Guo J., Rosen M.A., et al. Respiratory motion-compensated radial dynamic contrast-enhanced (DCE)-MRI of chest and abdominal lesions. Magn Reson Med 2008, 60:1135-1146.
40. Zhang M., Kono M. Solitary pulmonary nodules: Evaluation of blood flow patterns with dynamic CT. Radiology 1997, 205:471-478.
41. Ma S.H., Le H.B., Jia B.H., et al. Peripheral pulmonary nodules: Relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer 2008, 8:186.
42. Pauls S., Mottaghy F.M., Schmidt S.A., et al. Evaluation of lung tumor perfusion by dynamic contrast-enhanced MRI. Magn Reson Imaging 2008, 26:1334-1341.
43. Chen X., Park R., Tohme M., et al. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 2004, 15:41-49.
44. Beer A.J., Haubner R., Sarbia M., et al. Positron emission tomography using [18F]galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006, 12:3942-3949.
45. Beer A.J., Lorenzen S., Metz S., et al. Comparison of integrin aVb3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: A PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 2008, 49:22-29.
46. Morrison M.S., Ricketts S.A., Barnett J., et al. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 2009, 50:116-122.
47. Evans S.M., Joiner B., Jenkins W.T., et al. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer 1995, 72:875-882.
48. Raleigh J.A., Chou S.C., Arteel G.E., et al. Comparisons among pimonidazole Binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999, 151:580-589.
49. Rasey J.S., Koh W.J., Grierson J.R., et al. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989, 17:985-991.
50. Piert M., Machulla H.J., Picchio M., et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005, 46:106-113.
51. Ziemer L.S., Evans S.M., Kachur A.V., et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med 2003, 30:259-266.
52. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999, 40:177-183.
53. Chapman J.D., Engelhardt E.L., Stobbe C.C., et al. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998, 46:229-237.
54. Zhang X., Melo T., Ballinger J.R., et al. Studies of 99mTc-BnAO (HL-91): A non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys 1998, 42:737-740.
55. Rasey J.S., Wui-Jin K., Evans M.L., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996, 36:417-428.
56. Cherk M., Foo S., Poon A., et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006, 47:1921-1926.
57. Dehdashti F., Mintun M.A., Lewis J.S., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30:844-850.
58. Koh W.J., Bergman K.S., Rasey J.S., et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F 18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995, 33:391-398.
59. Koch C.J., Kruuv J., Frey H.E. Variation in radiation response of mammalian cells as a function of oxygen tension. Radiat Res 1973, 53:33-42.
60. Moeller B.J., Dreher M.R., Rabbani Z.N., et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005, 8:99-110.
61. Schwartz D.L., Powis G., Thitai-Kumar A., et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009, 8:947-958.
62. Zeng L., Ou G., Itasaka S., et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 2008, 99:2327-2335.
63. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res 2006, 12:5018-5022.
64. Nagy J.A., Benjamin L., Zeng H., et al. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008, 11:109-119.
65. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59:3374-3378.
66. Williams K.J., Telfer B.A., Shannon A.M., et al. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: Pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 2007, 6:599-606.
67. Williams K.J., Telfer B.A., Brave S., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004, 10:8587-8593.
68. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
69. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
70. Horsman M.R., Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006, 66:11520-11539.
71. Dutta P.R., Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007, 254:165-177.
72. Raben D., Helfrich B., Chan D.C., et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005, 11:795-805.
73. Chinnaiyan P., Huang S., Vallabhaneni G., et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005, 65:3328-3335.
74. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
75. Pore N., Jiang Z., Gupta A., et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006, 66:3197-3204.
76. Cerniglia G.J., Pore N., Tsai J.H., et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy andradiotherapy efficacy. PLoS ONE 2009, 4:e6539.
77. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: Variations on a theme. Oncogene 2008, 27:5497-5510.
78. Gupta A.K., Soto D.E., Feldman M.D., et al. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung 2004, 182:151-162.
79. Lee S.H., Kim H.S., Park W.S., et al. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 2002, 110:587-592.
80. Kim I.A., Bae S.S., Fernandes A., et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005, 65:7902-7910.
81. Prevo R., Deutsch E., Sampson O., et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008, 68:5915-5923.
82. Qayum N., Muschel R.J., Im J.H., et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009, 69:6347-6354.
83. Gupta A.K., Cerniglia G.J., Mick R., et al. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005, 65:8256-8265.
84. Jiang Z., Pore N., Cerniglia G.J., et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 2006, 67:9252-9259.
85. Pore N., Gupta A.K., Cerniglia G.J., et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: Implications for radiotherapy. Cancer Res 2006, 66:9252-9259.
86. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001, 85:881-890.
87. Swinson D.E., Jones J.L., Cox G., et al. Hypoxia-inducible factor-1 alpha in nonsmall cell lung cancer: Relation to growth factor, protease and apoptosis pathways. Int J Cancer 2004, 111:43-50.
88. Kim S.J., Rabbani Z.N., Dewhirst M.W., et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005, 49:325-335.
89. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001, 61:7992-7998.
90. Kon-no H., Ishii G., Nagai K., et al. Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. Lung Cancer 2006, 54:409-418.
91. Simi L., Venturini G., Malentacchi F., et al. Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer. Lung Cancer 2006, 52:59-66.
92. Swinson D.E., Jones J.L., Richardson D., et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003, 21:473-482.
93. Malentacchi F., Simi L., Nannelli C., et al. Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer. Lung Cancer 2009, 64:271-276.
94. Minami K., Saito Y., Imamura H., et al. Prognostic significance of p53, Ki-67, VEGF and glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002, 38:51-57.
95. Nguyen X.C., Lee W.W., Chung J.H., et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: Correlations and prognostic values. Eur J Radiol 2007, 62:214-219.